In vivo activity of thiophene-containing trisubstituted methanes against acute and persistent infection of non-tubercular Mycobacterium fortuitum in a murine infection model

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1188-1197

  Kashyap, Vivek Kr ^a   Gupta, Ravi Kr ^a   Shrivastava, Rahul ^a   Srivastava, Brahm S ^a   Srivastava, Ranjana ^a   Parai, Maloy Kumar ^a   Singh, Priyanka ^a   Bera, Saurav ^a   Panda, Gautam ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

Antimycobacterials; In vivo drug screening; NTM; Replicating and latent M. fortuitum

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; MOXIFLOXACIN; OFLOXACIN; SPARFLOXACIN; THIOPHENE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CELL COUNT; CELL VIABILITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG SCREENING; FEMALE; IMMUNE RESPONSE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; MYCOBACTERIUM AVIUM; MYCOBACTERIUM CHELONEI; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM KANSASII; MYCOBACTERIUM MARINUM; MYCOBACTERIUM SMEGMATIS; NON TUBERCULAR MYCOBACTERIUM FORTUITUM INFECTION; NONHUMAN; TH1 CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; FEMALE; METHANE; MICE; MICE, INBRED BALB C; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM INFECTIONS; SURVIVAL ANALYSIS; THIOPHENES; TREATMENT OUTCOME; VERO CELLS;

EID: 84859561619     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr592     Document Type: Article

References (32)

1. Katoch VM. Infections due to non-tuberculous mycobacteria (NTM). Indian J Med Res 2004; 120: 209-304.
2. Smith MB, Schnadig VJ, Boyars MC et al. Clinical and pathologic features of Mycobacterium fortuitum infections. An emerging pathogen in patients with AIDS. Am J Clin Pathol 2001; 116: 225-32.
3. Wallace RJ Jr., Swenson JM, Silcox VA et al. Spectrum of disease due to rapidly growing mycobacteria. Rev Inf Dis 1983; 5: 657-79.
4. Wolinsky E. Nontuberculous mycobacteria and asociated diseases. Am Rev Resp Dis 1979; 119: 107.
5. Griffith DE, Aksamit T, Brown-Elliott BA et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 2007; 175: 367-416.
6. Manabe YC, Bishai WR. Latent Mycobacterium tuberculosis -persistence, patience, and winning by waiting. Nat Med 2000; 6: 1327-9.
7. Wayne LG, Sohaskey CD. Nonreplicating persistence of Mycobacterium tuberculosis. Ann Rev Microbiol 2001; 55: 139-63.
8. Talaat AL, Trucksis M, Kane AS et al. Pathogenicity of Mycobacterium fortuitum and Mycobacterium smegmatis to goldfish, Carrasius auratus. Vet Microbiol 1999; 66: 151-61.
9. Saito H, Tasaka H. Comparison of the pathogenicity for mice of Mycobacterium fortuitum and Mycobacterium abscessus. J Bacteriol 1969; 99: 851-5.
10. Parti RP, Srivastava S, Gachhui R et al. Murine infection model for Mycobacterium fortuitum. Microbes Infect 2005; 7: 349-55.
11. Parti RPS, Shrivastava R, Srivastava S et al. A transposon insertion mutant of Mycobacterium fortuitum attenuated in virulence and persistence in a murine infection model that is complemented by Rv3291c of Mycobacterium tuberculosis. Microb Pathog 2008; 45: 370-6.
12. Deb DK, Srivastava KK, Srivastava R et al. Bioluminescent Mycobacterium aurum expressing firefly luciferase for rapid and high throughput screening of antimycobacterial drugs in vitro and in infected macrophages. Biochem Biophys Res Commun 2000; 279: 457-61.
13. Hickey MJ, Arain TM, Shawar RM et al. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob Agents Chemother 1996; 40: 400-7.
14. Flynn JL, Chan J. Tuberculosis: latency and reactivation. Infect Immun 2001; 69: 4195-201.
15. Scanga CA, Mohan VP, Joseph H et al. Reactivation of latent tuberculosis: variations on the Cornell murine model. Infect Immun 1999; 67: 4531-8.
16. Heifets L. Susceptibility testing of Mycobacterium avium complex isolates. Antimicrob Agents Chemother 1996; 48: 1759-67.
17. Gillespie SH, Morrissey I, Everett D. A comparision of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model. J Med Microbiol 2001; 50: 565-70.
18. Saquib M, Husain I, Sharma S et al. 2,3-Dideoxy hex-2-enopyranosid-4-uloses as promising new anti-tubercular agents: design, synthesis, biological evaluation and SAR studies. Eur J Med Chem 2011; 46: 2217-23.
19. Shandil RK, Jayaram R, Kaur P et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-82.
20. Wayne LG, Sramek HA. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994; 38: 2054-8.
21. Raja A. Immunology of tuberculosis. Indian J Med Res 2004; 120: 213-32.
22. Brinkmann V, Kristofic C. Regulation by corticosteroids of Th1 and Th2 cytokine production in human CD4+ effector T cells generated from CD45RO-and CD45RO+ subsets. J Immunol 1995; 155: 3322-8.
23. Daynes RA, Meikle AW, Araneo BA. Locally active steroid hormones may facilitate compartmentalization of immunity by regulating the types of lymphokines produced by helper T cells. Res Immunol 1991; 142: 40-5.
24. Howard AD, Zwilling BS. Reactivation of tuberculosis is associated with a shift from type 1 to type 2 cytokines. Clin Exp Immunol 1998; 115: 428-34.
25. Giordanetto F, Karlsson O, Lindberg J et al. Discovery of cyclopentaneand cyclohexane-trans-1,3-diamines as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg Med Chem Lett 2007; 17: 4232-41.
26. Kumar PR, Raju S, Goud PS et al. Synthesis and biological evaluation of thiophene [3,2-b] pyrrole derivatives as potential anti-inflammatory agents. Bioorg Med Chem 2004; 12: 1221-30.
27. Bonini C, Chiummiento L, De Bonis M et al. Synthesis, biological activity and modelling studies of two novel anti HIV PR inhibitors with a thiophene containing hydroxyethylamino core. Tetrahedron 2005; 61: 6580-9.
28. Brault L, Migianu E, Néguesque A et al. New thiophene analogues of kenpaullone: synthesis and biological evaluation in breast cancer cells. Eur J Med Chem 2005; 40: 757-63.
29. Parai MK, Panda G, Chaturvedi V et al. Thiophene containing triarylmethanes as antitubercular agents. Bioorg Med Chem Lett 2008; 18: 289-92.
30. Kumar S, Das SK, Dey S et al. Antiplasmodial activity of [(aryl)arylsulfanyl methyl]pyridine. Antimicrob Agents Chemother 2008; 52: 705-15.
31. Panda G, Parai MK, Srivastava AK et al. Design, synthesis and antitubercular activity of compounds containing aryl and heteroaryl groups with alkylaminoethyl chains. Indian J Chem B 2009; 48B: 1121-7.
32. Esteban J, Ortiz-Pérez A. Current treatment of atypical mycobacteriosis. Expert Opin Pharmacother 2009; 10: 2787-99.